Royal Bank Of Canada Increases Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $195.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target increased by equities researchers at Royal Bank Of Canada from $191.00 to $195.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 3.19% from the company’s previous close.

A number of other equities research analysts also recently commented on JAZZ. Morgan Stanley increased their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research report on Wednesday. Truist Financial boosted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Robert W. Baird increased their target price on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Needham & Company LLC lifted their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $213.85.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $188.97 on Wednesday. The business’s 50-day moving average is $169.18 and its two-hundred day moving average is $150.86. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.44. The firm has a market capitalization of $11.63 billion, a P/E ratio of -31.65, a P/E/G ratio of 1.06 and a beta of 0.26. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.51 earnings per share. Analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This represents a 39.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This trade represents a 10.29% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Farther Finance Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares during the last quarter. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $36,000. Hantz Financial Services Inc. grew its position in Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares during the last quarter. LRI Investments LLC purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at $38,000. Finally, Danske Bank A S acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $40,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat: Jazz reported Q4 revenue of ~$1.20B and EPS of $6.64, topping consensus and showing year-over-year revenue growth driven by neuroscience and oncology products. JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
• Positive Sentiment: Strong oxybate/Xywav growth is a core driver of the beat and underpins management’s optimism for 2026. Jazz Pharmaceuticals beats estimates on strong Xywav growth
• Positive Sentiment: 2026 revenue outlook raised: management projects $4.25B–$4.50B for 2026 while highlighting progress on rare-disease and oncology launches — a bullish forward signal. Jazz projects 4.25B–4.50B 2026 revenue
• Positive Sentiment: Multiple analyst price-target upgrades and bullish ratings after the print (Bank of America, Wells Fargo, Morgan Stanley, RBC) lift forward sentiment and imply substantial upside from current levels. Analyst price target raises TickerReport: BofA raise
• Neutral Sentiment: Detailed context available in the earnings call transcript and investor presentation for pipeline, launch timing and margin assumptions. Investors may want to review these for items that affect long-term modeling. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Near-term pullback/volatility drivers: the stock ran up into the print (near its 52‑week high), trading volume is elevated, and some investors are likely taking profits despite the beat — a plausible reason for the intraday decline.
• Negative Sentiment: Structural/valuation considerations: Jazz still has leverage on the balance sheet and reported a negative net margin in the background data; some investors may be cautious on margins and cash flow conversion as the company invests in launches. (See earnings coverage for metrics.) Earnings Call Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.